Biogen Newsroom

Leerink Partners Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $290

Futu News02:43

BMO Capital Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $164

Futu News02:43

Biogen's Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles

TipRanks02:13

Biogen Cut to Market Perform From Outperform by BMO Capital

Dow JonesDec 20 18:16

Biogen Analyst Ratings

BenzingaDec 20 18:06

BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164

BenzingaDec 20 18:06

Stifel Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $175

Futu NewsDec 16 19:32

Stifel Downgrades Biogen to Hold From Buy, Adjusts Price Target to $175 From $275

MT NewswiresDec 16 18:43

Biogen Analyst Ratings

BenzingaDec 10 20:41

B of A Securities Reinstates Neutral on Biogen, Announces $178 Price Target

BenzingaDec 10 20:39

Biogen Analyst Ratings

BenzingaDec 9 19:42

Jefferies Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $180

Futu NewsDec 9 19:31

Biogen's Modest Growth Prospects and Revenue Challenges Highlighted in Hold Rating

TipRanksDec 9 18:40

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Biogen (BIIB) and Edwards Lifesciences (EW)

TipRanksDec 6 02:14

Morgan Stanley Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $192

Futu NewsDec 6 01:35

RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)

TipRanksNov 28 09:49

Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250

Futu NewsNov 25 23:30

Jefferies Remains a Buy on Biogen (BIIB)

TipRanksNov 25 23:27

Biogen Is Maintained at Outperform by Mizuho

Dow JonesNov 21 21:19

Biogen Analyst Ratings

BenzingaNov 21 21:09